Ginkgo Bioworks Holdings Inc DNA is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates.
Ginkgo Bioworks said fourth-quarter revenue increased 363% year-over-year to $148 million, which beat the $94 million estimate.
The company reported a net loss from operations of $1.7 billion. Ginkgo Bioworks reported adjusted EBITDA of $1 million, which was up from a loss of $51 million in the fourth quarter of 2020.
Ginkgo Bioworks expects full-year 2022 revenue to be between $325 million and $340 million versus the $306 million estimate.
Ginkgo Bioworks is focused on building a platform to enable customers to program cells as easily as computers.
DNA 52-Week Range: $2.62 - $15.86
The stock was up 9.92% in after hours at $4.10 at press time.
Photo: mirerek8 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
